Surgeons may be able to reduce the invasiveness of breast cancer treatment by omitting the complete removal of axillary lymph nodes in specific patients, according to clinical evidence regarding sentinel node positivity.
- Axillary lymph node dissection (ALND) may be safely omitted in patients where only one or two sentinel lymph nodes are found to be positive for cancer.
- This conservative approach does not appear to compromise overall survival or disease-free survival rates.
- Avoiding full dissection significantly reduces the risk of long-term postoperative complications.
The Shift in Axillary Management
For decades, the standard of care for breast cancer patients with positive lymph nodes involved a full axillary lymph node dissection—the surgical removal of most of the lymph nodes in the armpit. The goal was to ensure all cancer cells were removed and to provide accurate staging. However, recent clinical data suggests that for a specific subset of patients, this aggressive approach may be unnecessary.
Current evidence indicates that when only one or two sentinel nodes—the first nodes to which cancer cells are most likely to spread from a primary tumor—test positive, the benefits of removing the remaining nodes do not outweigh the risks for patients undergoing breast-conserving surgery and whole-breast radiation.
Reducing Surgical Morbidity
The primary driver behind the move toward omitting full dissection is the reduction of surgical morbidity. ALND is associated with several significant long-term side effects that can diminish a patient’s quality of life.
The most prominent concern is lymphedema, a chronic condition characterized by the accumulation of lymph fluid in the arm, leading to swelling, heaviness and an increased risk of infection. Full dissection increases the likelihood of nerve damage, which can cause numbness or chronic pain in the arm and chest wall.
Clinical Considerations and Limitations
This approach is not a universal application for all breast cancer patients. The decision to omit a full lymph node dissection is typically reserved for patients who meet specific criteria, such as those receiving breast-conserving surgery (lumpectomy) followed by radiation therapy to the entire breast.
According to the research, the omission of ALND in these specific cases does not result in a significant increase in regional recurrence that would impact the patient’s overall survival. By relying on the sentinel node biopsy as a primary indicator, clinicians can avoid unnecessary surgery while maintaining oncological safety.
However, the evidence emphasizes that this strategy is specific to those with limited nodal involvement. Patients with three or more positive sentinel nodes, or those who are not candidates for radiation therapy, may still require a more extensive dissection to ensure the best possible outcome.
